Our previous study demonstrated berberine (BBR) and fluconazole (FLC) used concomitantly exhibited a synergism against FLC-resistant Candida albicans in vitro. We also suggested BBR played a major antifungal role in the synergism of FLC and BBR, while FLC increased intracellular BBR concentrations. Our following systematic structural modification and reconstruction of BBR core identified the novel scaffold of N-(2-(benzo [d][1,3]dioxol-5-yl)ethyl)-2-(substituted phenyl)acet-amide derivatives 7a-i, including B-7b and B-7d exhibiting remarkable synergistic antifungal activity and low cytotoxicity. Here, the study mainly investigated the synergistic activity of FLC and B-7b and the underlying mechanism. In vitro interaction of FLC and B-7b was investigated against 30 FLC-resistant clinical isolates of C. albicans and non-C. albicans species, including Candida tropicalis, Candida parapsilosis, Candida glabrata, Candida krusei and Cryptococcus neoformans. The potent synergistic activity of B-7b in combination with FLC against FLC-resistant C. albicans was found through the checkerboard microdilution assay. The findings of agar diffusion tests and timekill curves confirmed its better synergism with FLC. And as expected, B-7b exhibited much lower cytotoxicity than BBR to human umbilical vein endothelial cells. In contrast to BBR, we found that endogenous ROS augmentation was not involved in the synergism of FLC and B-7b. According to the results from our present comparative proteomic study, it seemed that the disruption of protein folding and processing and the weakening of cells' self-defensive ability contributed to the synergism of FLC and B-7b. Together, these results suggested novel scaffold BBR derivative B-7b could be a promising synergist in combination with FLC for the treatment of invasive fungal infections.
Introduction
Candida albicans, one of prevalent human fungal pathogens, mainly causing superficial mycoses, invasive mucosal infections, and disseminated systemic disease, is still the most common pathogenic fungus, and the infected patients have a mortality rate of approximately 40%, in the experiments, yeast-phase cells of the various strains were grown YPD broth overnight in a rotary shaker at 30°C.
Agents
Drugs prepared in dimethyl sulfoxide (DMSO) included FLC (Pfizer-Roerig Pharmaceuticals, New York, NY), BBR (Sigma-Aldrich, St. Louis, MO) and BBR derivatives B-8, B-7b and B-7d (Fig 1) structured and identified by methods shown in [32] , and their initial stored concentration was 6.4 mg/ml in DMSO [27] .
Checkerboard microdilution assay
The in vitro MICs of the compounds against all 30 clinical isolates of C. albicans were determined by the microbroth dilution method according to the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) as described previously [27] . The initial concentration of fungal suspension in RPMI 1640 medium was 10 3 CFU/ml, and the final concentrations ranged from 0.125 to 64 μg/ml for FLC and 1 to 32 μg/ml for B-7b. The final concentration for FLC or B-7b alone ranged from 0.125 to 64 μg/ml. 96-well flat-bottomed microtitration plates were incubated at 35°C for 24 h or 72 h. Optical density was measured at 630 nm. MIC 80 were determined as the lowest concentration of the drugs (alone or in combination) that inhibited growth by 80%, compared with that of drug-free wells. The data obtained by the checkerboard microdilution assays were analyzed using the model-fractional inhibitory concentration index (FICI) method based on the Loewe additivity theory. The fractional inhibitory concentration index (FICI) is defined as the sum of the MIC of each drug when used in combination divided by the MIC of the drug used alone. Synergy and antagonism were defined by FICIs of 0.5 and >4, respectively. An FICI result of >0.5 but 4 was considered indifferent [33] . Agar diffusion test C. albicans 103 (one FLC-resistant isolate with a MIC of >64 μg/ml for B-7b) was tested by agar diffusion assay as described previously [27] . A 3-ml aliquot of 10 6 -CFU/ml suspension was spread uniformly onto the yeast extract-peptone-dextrose agar plate with or without 4μg/ml FLC. Then, 6-mm paper disks impregnated with FLC and B-7b alone or in combination were placed onto the agar surface. There was 5μl of DMSO in control disks. Inhibition zones were measured after incubation at 35°C for 48 h.
Time-kill test
C. albicans 103 in RPMI 1640 medium was prepared at the starting inoculum of 10 3 CFU/ml or 10 5 CFU/ml. The concentrations were 4 μg/ml of B-7b and 8 μg/ml of FLC. DMSO comprised <1% of the total test volume. At predetermined time points (0, 4, 8, 12, 16, 24, 36 and 48 h) after incubation with agitation at 35°C in a shaking incubator, 100-μl aliquot was removed from every solution and serially diluted 10-fold in sterile water. A 100-μl aliquot from each dilution was spread on the sabouraud dextrose agar plate. Colony counts were determined after incubation at 35°C for 48 h. Synergism and antagonism were defined as a respective increase or decrease of !2 log 10 CFU/ml in antifungal activity produced by the combination compared with that by the more active agent alone after 24 h, while a change of <2 log 10 CFU/ ml was considered indifferent [27] .
Cytotoxicity evaluation of BBR derivatives using XTT assay
Human umbilical vein endothelial cell (HUVEC) was cultured in DMEM medium (HyClone) supplemented with 10% fetal bovine serum (HyClone). The cytotoxic effect of B-7b on HUVEC viability was assessed by the XTT assay [34] . Briefly, cells (3×10 3 cells/well) were cultured in 96-well microtiter plates and treated with different concentrations of B-7b for 24 h. At the end of incubation, 50 μL of PMS-XTT solution (final concentration, 50 μg of XTT and 0.38 μg of PMS per well) was added to each well and incubated at 37°C for 4 h. Absorbance at 450 nm was measured using the Eliza Plate Reader.
Protein sample preparation and NanoLC-MS/MS
FLC-resistant C. albicans 103 cells (OD 600 = 0.1) were treated or untreated with FLC (64μg/ml) and/or B-7b (16 μg/ml) for 9 h at 30°C. Cells were harvested and washed with phosphate-buffered saline (PBS, pH 7.4) buffer. Next, the cell pellet was lysed in 10 ml of lysis buffer [50 mM Tris, 1.5 mM EDTA, 1% (v/v) Triton×100, 0.4% (w/v) SDS, pH 7.5] and 20 ml of 0.5 mm diameter glass beads (Biospec, Bartlesville, OK) by vortexing for 30 seconds and cooling on ice for 30 seconds repeatedly in a Mini Bead-beater (Biospec) until at least 80% of the cells had been lysed as determined by phase-contrast microscopic examination. After centrifugation at 13 000 g for 5 min, the clarified protein supernatant was determined using the RC DC Protein Assay Kit (Bio-Rad, Herclues, CA) and according to the manufacturer's directions. The above obtained protein supernatant was applied to an EASY-nano liquid chromatography (LC) system (Proxeon Biosystem) coupled online to an ESI-LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific) as a previously described method [35] . The database searches were performed with the following parameters: Candida Genome Database (CGD), C. albicans SC5314_version_A22-s04-m01-r04_orf_trans_all.fasta. Protein abundance was calculated from all qualified corresponding peptides matched to that protein and final results were filtered using a 1% false discovery rate (FDR).
Bioinformatic analysis
To investigate biological significance, the identified differential proteins in each comparison were input into DAVID bioinformatics resources 6.7 (the Database for Annotation, Visualization, and Integrated Discovery, http://david.abcc.ncifcrf.gov/) for functional annotation and KEGG (the Kyoto Encylopedia of Genes and Genomes) pathway analysis [36] . Briefly, DAVID functional annotation and KEGG pathway analysis were performed on the list of differential proteins with differential ratio of over ±1.2 and a nominal p-value of less than 0.05 in each comparison. For the Gene Ontology (GO) enrichment in DAVID, the GO terms of "Biological Process", "Cellular Component" and "Molecular Function" were used, and only the terms that reported a p-value of 0.05 and count number !5 proteins were selected. The signaling pathways were identified and mapped using DAVID and the KEGG Automatic Annotation Server (KAAS) [37] . The KEGG pathways with at least 5 proteins and p-value of <0.05 were identified as enriched.
Further, protein-protein interaction (PPI) networks of the differential proteins were predicted and analyzed using STRING v9.1 (Search Tool for the Retrieval of Interacting Genes) database [38] . STRING, a web resource (http://string-db.org/) dedicated to protein-protein interactions including direct (physical) and indirect (functional) associations, quantitatively integrates information from numerous sources including genomic context, high-throughput experiments, (Conserved) co-expression and previous knowledge. Known and predicted protein-protein interactions are scored and integrated, resulting in comprehensive protein networks currently covering 5,214,234 proteins from 1133 organisms in the STRING database. This analysis gave uniquely comprehensive coverage of both experimental and predicted interaction information with a relative confidence score, implying that only interactions with high level of confidence were extracted and considered as valid links for the PPI network [38] [39] [40] . In a given network, proteins are represented as nodes and the interactions are defined as edges (lines), and thicker edges represent stronger associations. For a PPI network, the majority of the nodes were linked with each other, while some of altered proteins were isolated without partners. The "hub" proteins were proteins with a number of edges, meaning the capability of physically interacting with many partners.
Statistical analysis
At least three biological replicates were performed for all experiments unless otherwise indicated. Analysis of variance (ANOVA) was used when multiple groups were analyzed and the two-tailed Student's t-test was used for analysis of two groups, with paired analysis when appropriate. Statistical significance was set at a p value of 0.05, 0.01 or 0.001, indicated by Ã , ÃÃ , ÃÃÃ , respectively.
Results

Comparison of the activities of three BBR derivatives and BBR against FLC-resistant C. albicans
The highly effective in vitro synergism of FLC and BBR against FLC-resistant clinical isolates of C. albicans has been verified [27] . other two compounds. The statistical analysis for colony counts indicated that B-7b had better synergistic activity than the other two compounds in combination with FLC (10 μg/ml) against C. albicans 103 with the initial inoculum of 10 5 CFU/ml, though weaker than that of BBR ( Fig 2B) .
Further to visualize their synergistic antifungal effect, all compounds and the combination with FLC (4 μg/ml) were analyzed by agar diffusion tests ( Fig 2C) . All compounds (BBR, B-8, B-7b and B-7d) had no antifungal activity in small amounts at 4 μg alone (Fig 2C1) . At 4 μg, BBR combining with FLC showed no synergistic antifungal activity. In contrast, the three BBR derivatives showed potent synergistic antifungal effects on the agar plate with 4 μg/ml FLC (Fig 2C2) . The mean diameters of the inhibitory zones for BBR, B-8, B-7b and B-7d were 0, 25.2, 27.0 and 26.3 mm, respectively. In addition, as shown in Fig 2C3, the sizes of the inhibitory zones were 0, 17.1, 17.6 and 17.6 mm around disks impregnated with 2 μg FLC plus compounds (BBR, B-8, B-7b and B-7d), respectively. In small amounts (such as 4 μg), B-7b had slightly better (or the same) synergistic antifungal activity compared with B-8 and B-7d, but much better than BBR. Therefore, we conducted all subsequent studies with B-7b as a representative example.
In combination with FLC, B-7b at lower concentrations exhibits better synergistic activity than BBR against FLC-resistant C. albicans
As the above description, in small amounts at 4 μg, B-7b had more powerful synergistic effect than BBR (Fig 2C) . In order to determine whether B-7b at lower concentrations in combination with FLC showed better synergistic activity than that of BBR against FLC-resistant C. albicans 103, their synergism was also conμrmed by time-killing test (Fig 3) . BBR (4 μg/ml), B-7b (4 μg/ml) or FLC (8 μg/ml) alone had no effect on the growth of C. albicans 103 after 48 h. However, the antifungal activity of FLC was dramatically raised by addition of BBR or B-7b. Under the initial inoculum of 10 3 CFU/ml (Fig 3A) , the combination of FLC with BBR or B-7b respectively produced a 4.56 or 5.24-log 10 -CFU/ml decrease compared with the number of CFU produced by 8 μg/ml of FLC alone at 48 h (Table 1) . Given the beginning inoculum of 10 5 CFU/ml (Fig 3B) , the FLC+BBR or FLC+B-7b combination yielded 2.22 or 3.12-log 10 -CFU/ml decrease compared with the FLC alone at 48 h ( Table 1) . Despite of the starting inoculum, the combination of FLC and B-7b yielded a significant decrease of CFU/ml compared with the combination of FLC and BBR at both 24 h and 48 h (Fig 3C and 3D) . Interestingly, the significance level for the synergistic effect of FLC and B-7b compared with that of BBR was observed earlier (at 24 h) and much more prominent (p <0.001), when the initial inoculum declined from 10 5 CFU/ml to 10 3 CFU/ml (Fig 3C and 3D) .
To investigate the lower dosage of B-7b which in combination with FLC still exhibits its synergism, different concentrations of B-7b, FLC and the combination of B-7b and FLC (2 μg) were analyzed by agar disk diffusion assay as described in detail previously [27] . B-7b alone at 8, 4, 2, 1 μg per disc had no antifungal activity against the FLC-resistant C. albicans 103 ( Fig  4A) . While FLC at 2 μg per disc showed only weak inhibition effect against C. albicans, the halo surrounding the disc was cloudy with colony ( Fig 4A and 4C) . B-7b at 2μg still showed potent synergistic antifungal effect on the agar plate containing 4 μg/ml FLC (Fig 4B) . The mean FLC-resistant C. albicans 103 were treated with FLC (8 μg/ml), B-7b (4 μg/ml), BBR (4 μg/ml), FLC+ B7b (8+4) μg/ml and FLC+ BBR (8+4) μg/ml by using initial inoculums of 10 3 CFU/ml (A, C) and 10 5 CFU/ml (B, D). Aliquots were obtained at the indicated time points and serially dilutions were spread on agar plates. Colony counts were determined after 48h incubation. B-7b has much lower cytotoxicity when compared to BBR in vitro It is necessary to assess the toxicity of B-7b because of the high toxicity of BBR itself [30, 31] . In the study, in vitro cytotoxic effect of B-7b against HUVEC was performed via XTT assays. As shown in Fig 5, B-7b had no toxic effect on HUVEC at the concentration of 128 μg/ml, while BBR significantly (p <0.001) reduced cell viability (cell viability <50%) at concentrations !128 μg/ml. the results indicated that B-7b showed much lower toxicity and was quite promising when compared to BBR. Table 2 . The MICs of B-7b or FLC alone against all tested strains were >64 μg/ml, respectively. However, the combination of FLC and B-7b markedly reduced the MIC 80 s, and the median FICI was 0.016 (range, 0.012 to 0.07), while the median FICI of BBR+FLC was 0.034 (range, 0.017 to 0.127) as shown in the previous report [27] . B-7b in combination with FLC displayed powerful synergism in all 30 FLC-resistant C. albicans (100%) tested, according to the analysis of FICI method.
The combination of FLC and B-7b against varied yeast strains
We also tested antifungal activity of B-7b alone or in combination with FLC in other yeast strains (FLC-sensitive C. albicans, C. neoformans, C. tropicalis, C. krusei, C. parapsilosis and C. glabratas) ( Table 3 ). The range of MICs of B-7b tested alone against all these strains were still >64 μg/ml. When in combination with FLC, the MICs of B-7b ranged from 1 μg/ml to 32 μg/ ml. In C. glabratas and C. krusei, no synergistic effect was shown. However, the MIC of FLC was reduced from >64 μg/ml to 2 μg/ml in C. tropicalis after in combination with B-7b. Notably, we observed that FLC and B-7b did not display synergism against FLC-sensitive C. albicans SC5314 (Table 3) .
Functional annotation and pathway analysis
Our previous study suggested that mitochondrial aerobic respiration shift and endogenous ROS augmentation contributed to the synergistic action of FLC + BBR against FLC-resistant C. albicans [29] . However, our present study did not determined endogenous ROS augmentation involved in the synergistic mechanism of FLC and B-7b (S1 Fig). To get an insight on the underlying synergistic mechanism of FLC and B-7b against FLC-resistant isolates, a comprehensive comparative proteomic analysis was carried out in our study. We identified 2078 proteins in C. albicans using nano LC-MS/MS (Fig 6A) , and performed three grouped comparisons to identify patterns of differential proteins (Fig 6C, 6D and 6E) shown in Fig 6B and S1 Table. The pathway analysis and functional annotation using DAVID for differential proteins overrepresented were summarized in Table 4 and S2 Table, respectively. According to the above analysis, the steroid biosynthesis pathway was significantly (p <0.05) enriched in both comparison 1 (FLC treated versus Control sample) and 2 (FLC+B-7b treated versus Control sample) as shown in Table 4 and Fig 7A. Consistent with known protein annotation previously [41, 42] , proteins including Erg1, Erg3, Erg4, Erg6, Erg251, Erg11, and Erg10 involved in ergosterol biosynthesis were all up-regulated in FLC-and FLC+B-7b-treated sample compared to Control sample (Fig 7B) .
Subsequently, we paid attention to comparison 3 (FLC+B-7b-treated sample versus FLCtreated sample). We observed differential protein sets (Mpd1, Msi3, Sec61, Stt3, Skp1) were enriched in the pathway of Protein processing in endoplasmic reticulum (p = 0.03289, Table 4 ). The majority of these proteins (4/5) involved in this pathway were up-regulated (Fig 8) , while only the protein Skp1, which was putative subunit D of kinetochore protein complex CBF3 and contributed to ubiquitin protein ligase activity in Saccharomyces cerevisiae (S. cerevisiae) [43, 44] , was significantly down-regulated and had no any interactions with other four proteins as analyzed by STRING (Fig 9A) .
Besides, another important finding was that differential proteins from comparison 3 were also significantly classified into some crucial GO categories, such as protein folding and positive regulation of defense response (S2 Table) . Compared to FLC-treated sample, as shown in Fig 9B, four out of five proteins (Cyp1, Rbp1, Ess1, Cpr6, Cct2) enriched in protein folding were remarkable down-regulated in FLC+B-7b-treated sample, and three down-regulated proteins (Cyp1, Rbp1, Ess1) showed associations with high confidence score >0.7 (Fig 9A) . Particularly, proteins (Eno1, Fba1, Tdh1, Pgk1, Adh1) involved in positive regulation of defense response were all significantly decreased (Fig 9C) , and exhibited physical or functional interaction networks with high confidence score >0.8 (Fig 9A) . Interestingly, it was worthy note that Adh1, Ura2 and Rpa190 connected with many partners were dramatically down-regulated (p <0.05, Fig 9A) , and became connectors among positive regulation of defense response, amino acid metabolism (arginine, alanine, aspartate, glutamate and proline metabolism, shown in Table 4 ) and ribosome though in which differential proteins (e.g. Rpl7, Rps15, Rps3 and Rpl21A) were not significantly enriched, suggesting they might be "hub" proteins in C. albicans cells treated with FLC and B-7b.
Discussion
Previous researches have demonstrated the mechanism of synergism against FLC-resistant C. albicans such as: increasing reactive oxygen species (ROS) to promote apoptosis [45] , and inhibiting drug efflux pumps to increase intracellular drug concentration [46, 47] . For the synergism of FLC and BBR, our previous comparative proteomic analysis suggested that mitochondrial aerobic respiration shift and endogenous ROS augmentation contributed to the synergistic effect of FLC and BBR in FLC-resistant C. albicans [29] .
Based on the above findings, we further investigated the synergistic mechanism of FLC and B-7b against FLC-resistant C. albicans. Surprisingly, the synergistic action of FLC and B-7b did not lead to the increased generation of endogenous ROS in the study (S1 Fig). We also found that B-7b and FLC did not have synergism against FLC-sensitive C. albicans (Table 3) , and it seems that the synergistic antifungal activity of FLC+B-7b is relevant to FLC resistance. To further understand how FLC and B-7b worked synergistically against FLC-resistant C. albicans, we employed a comparative proteomic study in FLC-resistant C. albicans 103 cells untreated or treated with FLC and/ or B-7b. The proteins (such as Erg1, Erg3, Erg4, Erg6, Erg10, Erg24, Erg251 and Erg11) involved in the ergosterol biosynthesis pathway were all up-regulated in comparison 1 or 2 (Fig 7) , consisting with previous reports [41, 42] , while only one of these eight proteins (i.e. Erg4) was significantly changed in comparison 3, suggesting that the combination of FLC and B-7b had very weak or even no effect on the ergosterol biosynthesis pathway. KEGG and GO analysis first indicated that proteins involved in protein processing in endoplasmic reticulum and protein folding were significantly changed, such as remarkable down-regulated protein Cyp1, Rbp1 and Ess1 which are required for protein processing and growth in C. albicans [48] , suggesting the impact of FLC+B-7b on the growth of FLC-resistant C. albicans could occur through modulation of proteins associated with the protein processing pathway. In addition, according to the GO and PPI networks analysis, we observed that positive regulation of defense response-related proteins (i.e. Eno1, Fba1, Tdh1, Pgk1 and Adh1) were all significantly down regulated (Fig 9C) and co-expressed, and therefore it seemed that the synergistic effect of FLC and B-7b could weaken the cell defense response to drugs.
Adh1, an immunogenic alcohol dehydrogenase, play a role in adherence and response to the extracellular matrix and stimulus [49, 50] . In S. cerevisiae, Ura2 is bifunctional carbamoylphosphate synthetase/aspartate transcarbamylase and catalyzes the first two enzymatic steps in the de novo biosynthesis of pyrimidines [51, 52] , while it is not verified by direct assays and still uncharacterized in C. albicans. Rpa190 is yet uncharacterized in C. albicans, while it is verified Synergism of Berberine Derivative B-7b and Fluconazole to be RNA polymerase I largest subunit A190 in S. cerevisiae [53] . Therefore, the putative "hub" proteins Adh1, Ura2 and Rpa190 constructing the interconnectivity of three functional categories (i.e. positive regulation of defense response, amino acid metabolism and ribosome), shown in Fig 9A, may play critical roles in the synergistic mechanism of B-7b and FLC against FLC-resistant C. albicans, and further studies are necessary to be performed. In conclusion, our study first investigated the synergistic antifungal activity and possible mechanism of novel scaffold of BBR derivatives. The better synergistic activity and much lower cytotoxicity suggested that the representative compound B-7b could serve as a promising lead compound for further research. The results presented here offer the first insights into the synergistic mechanism of FLC and B-7b. Analysis of global protein patterns shift suggested positive regulation of defense response and protein processing involved in the synergism. Further studies to identify the target of B-7b should be carried out. 
